Table 3.
WD GEP-NETs patient characteristics.
| Localization of PT (n = 96) | n (%) |
|---|---|
| GI-NET | 72 (75.0) |
| Jejunum-ileum | 45 (62.5) |
| Duodenum | 10 (13.9) |
| Rectum | 8 (11.1) |
| Appendix | 5 (6.9) |
| Colon | 2 (2.8) |
| Stomach | 1 (1.4) |
| Ampulla | 1 (1.4) |
| p-NET | 22 (22.9) |
| Unknown (UK) | 2 (2.1) |
| Hormonal Syndrome (n = 96) | |
| Yes (93.2% carcinoid syndrome; 6.8% gastrinomas) | 44 (45.8) |
| No | 43 (44.8) |
| Unknown (UK) | 9 (9.4) |
| Grading (WHO 2010)—n = 96 | |
| NETG1 | 64 (66.7) |
| NETG2 | 26 (27.1) |
| Unknown (UK) | 6 (6.3) |
| Staging (ENETS)—(n = 96) | |
| Local disease | 30 (31.3) |
| Loco regional disease | 16 (16.7) |
| Disseminated disease | 42 (43.8) |
| Unknown (UK) | 8 (8.3) |
| Past History | |
| Family History of T2-DM (n = 81) | 39 (48.1) |
| Hypertension (n = 96) | 61 (63.5) |
| Dyslipidemia (n = 96) | 60 (62.5) |
| T2DM (n = 96) | 17 (17.7) |
| NET Treatment | |
| Endoscopic therapy (n = 95) | 11 (11.6) |
| Surgery (n = 96) | 73 (76.8) |
| SA (n = 95) | 60 (62.5) |
| Liver ablative therapies (n = 95) | 28 (29.5) |
| PRRNT (n = 95) | 7 (7.4) |
| Chemotherapy (n = 96) | 1 (1.0) |
| Target therapies (n = 96) | 0 (0.0) |